Colchicine in Percutaneous Coronary Intervention

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

714 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inflammation in the arteries of the heart may increase the risk of cardiac death. The proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory medication, colchicine, on reducing damage caused by opening up a blockage in the arteries of the heart. With its quick onset of action and excellent safety profile, colchicine may have the potential to reduce risk of major adverse events related to the heart. This research also seeks to better understand the role of neutrophils, the most common type of inflammatory white blood cell in the body, when there is damage to the heart.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ESCALATion of Medical Therapy Following Multimodality Plaque Evaluation in High-risk Chronic Coronary Syndromes

NCT06469528

Coronary Artery Disease

NOT_YET_RECRUITING PHASE3

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

NCT06909565

Percutaneous Coronary Intervention Peripheral Endovascular Intervention

RECRUITING PHASE4

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

NCT03471611

Atherosclerosis, Coronary

COMPLETED PHASE1

Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)

NCT05739929

Coronary Artery Disease

UNKNOWN PHASE3

Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease

NCT06212271

Peripheral Artery Disease

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will use colchicine as a tool to elucidate the role of neutrophil activation during acute vascular injury, and to explore the association between neutrophil activation and adverse cardiovascular outcomes. Colchicine reduces cell surface expression of selections, adhesion molecules key to neutrophil recruitment after vascular injury. Daily colchicine use is associated with reduced adverse cardiovascular events in stable atherosclerosis. Using a clinical percutaneous coronary intervention (PCI) model, the investigators evaluate whether pre-procedural colchicine (1.8 mg oral load over one hour) reduces the rate of post-PCI adverse cardiovascular outcomes in the context of a double-blind placebo-controlled randomized study. The investigators will also characterize neutrophil biology in acute vascular injury and the effects of colchicine on neutrophil biology in this setting.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colchicine

Colchicine 1.8 mg PO over 1 hour

Group Type ACTIVE_COMPARATOR

Colchicine vs Placebo

Intervention Type DRUG

Colchicine vs Placebo 1.8 mg PO over 1 hour

Placebo

Matching placebo

Group Type PLACEBO_COMPARATOR

Colchicine vs Placebo

Intervention Type DRUG

Colchicine vs Placebo 1.8 mg PO over 1 hour

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colchicine vs Placebo

Colchicine vs Placebo 1.8 mg PO over 1 hour

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Referred for possible PCI

Exclusion Criteria

* Colchicine use within 1 month
* History of colchicine intolerance
* Glomerular filtration rate \<30mL/minute or on dialysis (due to the need to adjust colchicine dose in this setting)
* Active malignancy or infection (major confounder with increased inflammatory markers)
* History of myelodysplasia (due to suggested cautionary use of colchicine in this setting)
* High-dose statin load \<24 hours prior to procedure (major confounder that is known to reduce inflammatory levels in 12 to 24 hours)
* Use of anti-inflammatory agents (except aspirin) within 5 halflives of the individual drug
* Use of strong Cytochrome P450, Family 3, Subfamily A, Polypeptide 4 (CYP3A4) and/or P-glycoprotein inhibitors (e.g. ritonavir, ketoconazole, clarithromycin, cyclosporine, diltiazem and verapamil, again due to drug interactions)
* Unable to consent
* Participating in a competing study
* Any significant condition or situation that may put the subject at higher risk, confound the study results or interfere with adherence to study procedures

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No